ATE364632T1 - Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation - Google Patents

Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation

Info

Publication number
ATE364632T1
ATE364632T1 AT01123851T AT01123851T ATE364632T1 AT E364632 T1 ATE364632 T1 AT E364632T1 AT 01123851 T AT01123851 T AT 01123851T AT 01123851 T AT01123851 T AT 01123851T AT E364632 T1 ATE364632 T1 AT E364632T1
Authority
AT
Austria
Prior art keywords
human origin
antibodies
thrombocyte aggregation
inhibiting
inhibiting thrombocyte
Prior art date
Application number
AT01123851T
Other languages
English (en)
Inventor
Claudia Buettner
Meike Schwarz
Stefan Knackmuss
Karlheinz Peter
Peter Roettgen
Melvyn Little
Original Assignee
Affimed Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Therapeutics Ag filed Critical Affimed Therapeutics Ag
Application granted granted Critical
Publication of ATE364632T1 publication Critical patent/ATE364632T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01123851T 2001-10-05 2001-10-05 Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation ATE364632T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01123851A EP1300419B1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen Ursprungs zur Hemmung der Thrombozytenaggregation

Publications (1)

Publication Number Publication Date
ATE364632T1 true ATE364632T1 (de) 2007-07-15

Family

ID=8178855

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01123851T ATE364632T1 (de) 2001-10-05 2001-10-05 Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation

Country Status (7)

Country Link
US (1) US7812136B2 (de)
EP (1) EP1300419B1 (de)
JP (2) JP4504017B2 (de)
AT (1) ATE364632T1 (de)
DE (1) DE60128914T2 (de)
ES (1) ES2288900T3 (de)
WO (1) WO2003031476A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2422881A1 (en) * 2000-10-13 2002-04-18 Uab Research Foundation Human anti-epidermal growth factor receptor single-chain antibodies
US8455627B2 (en) * 2001-10-05 2013-06-04 Affimed Therapeutics, Ag Human antibody specific for activated state of platelet integrin receptor GPIIb/IIIa
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
ES2436170T3 (es) * 2003-12-03 2013-12-27 The Scripps Research Institute Anticuerpos y péptidos específicos de la integrina alfa II beta3
CA2613691A1 (en) * 2005-07-05 2007-01-11 Baker Medical Research Institute Anticoagulation agent and uses thereof
WO2007139208A1 (ja) * 2006-05-26 2007-12-06 Kurume University 血小板の粘着凝集反応に関連する疾患の予防用又は治療用の医薬組成物、および、そのスクリーニング方法
US8563690B2 (en) 2008-11-03 2013-10-22 The Board Of Trustees Of The University Of Illinois Modulation of platelet aggregation
CN102459591B (zh) 2009-05-20 2015-05-13 诺维莫尼公司 合成性的多肽文库以及用于建立具有天然多样性的多肽变体的方法
TW201217527A (en) 2010-07-09 2012-05-01 Biogen Idec Hemophilia Inc Processable single chain molecules and polypeptides made using same
HUE049154T2 (hu) 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
US9486507B2 (en) 2011-06-10 2016-11-08 Biogen Ma Inc. Pro-coagulant compounds and methods of use thereof
CA2875247A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Chimeric clotting factors
WO2013185113A1 (en) 2012-06-08 2013-12-12 Biogen Idec Ma Inc. Procoagulant compounds
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
KR101451340B1 (ko) * 2012-08-02 2014-10-15 (주)애드바이오텍 모발 생장 촉진용 조성물
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
EP3065769A4 (de) 2013-11-08 2017-05-31 Biogen MA Inc. Prokoagulatorische fusionsverbindung
EP3215175A4 (de) 2014-11-06 2018-06-27 Scholar Rock, Inc. Anti-pro/latentes-myostatin-antikörper und verwendungen davon
AR105654A1 (es) * 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
JP6686768B2 (ja) * 2015-09-03 2020-04-22 東ソー株式会社 細胞の分離回収方法
HRP20211081T1 (hr) 2015-09-15 2021-10-15 Scholar Rock, Inc. Anti-pro/latentna miostatinska protutijela i njihove uporabe
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
NZ789269A (en) 2016-06-13 2026-01-30 Scholar Rock Inc Use of myostatin inhibitors and combination therapies
EP4218817A3 (de) 2017-01-06 2023-09-06 Scholar Rock, Inc. Verfahren zur behandlung von stoffwechselerkrankungen durch hemmung der myostatinaktivierung
CN114340735B (zh) 2019-06-28 2024-11-12 璟尚生物制药公司 突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
EP4638496A1 (de) 2022-12-22 2025-10-29 Scholar Rock, Inc. Selektive und potente hemmende antikörper der myostatinaktivierung

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557535B1 (de) 1991-09-17 1997-12-17 Teijin Limited Humaner monoklonaler antikörper gegen glycoprotein-iib/iiia
US6955900B1 (en) * 1993-02-02 2005-10-18 The Scripps Research Institute Methods for producing polypeptide binding sites, monoclonal antibodies and compositions thereof
US6265150B1 (en) * 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
CA2293693A1 (en) * 1997-06-06 1998-12-10 Asat Ag Applied Science & Technology Anti-gpiib/iiia recombinant antibodies
IL144559A0 (en) * 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
WO2003031476A1 (en) 2003-04-17
DE60128914T2 (de) 2008-05-08
US20070218067A1 (en) 2007-09-20
DE60128914D1 (de) 2007-07-26
ES2288900T3 (es) 2008-02-01
JP2010029203A (ja) 2010-02-12
US7812136B2 (en) 2010-10-12
JP4504017B2 (ja) 2010-07-14
EP1300419A1 (de) 2003-04-09
JP2005514009A (ja) 2005-05-19
EP1300419B1 (de) 2007-06-13

Similar Documents

Publication Publication Date Title
ATE364632T1 (de) Antikörper menschlichen ursprungs zur hemmung der thrombozytenaggregation
MA30153B1 (fr) Anticorps anti-ox40l et methodes correspondantes
CY1113224T1 (el) Νεο αντισωμα αντι-ρlgf
DE602006013029D1 (de) Anti-egfr-antikörper
FR15C0034I1 (fr) Anticorps humains specifiques pour le kdr et leurs utilisations
NO2017032I1 (no) bezlotoksumab
CY1113087T1 (el) Ανθρωπινα αντισωματα εναντιον δελτα-παρομοιου προσδεματος 4
ATE481979T1 (de) Kombination aus einem anti-edb-fibronectin- domänen-antikörper/il2-fusionsprotein und einem weiteren kleinen molekül
CY1117124T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟΙ ANTΑΓΩΝΙΣΤΕΣ ΑΝΤΙ-β7 ΚΑΙ ΧΡΗΣΕΙΣ ΑΥΤΩΝ
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
BRPI0506679A (pt) métodos de tratar osteoartrite com antagonistas de il-6
WO2003074679A3 (en) Antibody optimization
DK1699826T3 (da) Syntetiske immunoglobulindomæner med bindende egenskaber konstrueret i regioner af molekylet forskellig fra de komplementaritets-bestemmende domæner
NO20085104L (no) Antagonistisk anti-humant CD40-monoklonalt antistoff
SI1557462T1 (sl) Celice monocitnega izvora, ki inducirajo sprejemljivost transplantata, kot tudi njihova priprava in uporaba
WO2006102200A3 (en) Docetaxel immunoassay
DK1864129T3 (da) Doxurubicin-immunassay
DE602005022315D1 (en) Taxol-immunoassay
EE200300092A (et) EDb-fibronektiinidomeeni retseptor
DE10108995A1 (de) Substituierte Pyrimidinon-Derivate als Liganden von Integrinrezeptoren
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
DE50104758D1 (de) Einrichtung zum Verbinden beweglicher Teile mit Strukturbauteilen von Flugzeugen od. dgl.
EP1408112A4 (de) An die katalytische mt4-mmp-domäne bindender monoklonaler antikörper
UA98100C2 (ru) Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его
CY1115900T1 (el) Αντισωματα αντι-ephb4 και μεθοδοι χρησης αυτων

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1300419

Country of ref document: EP